Background
==========

Millions of people in the US suffer from chronic obstructive pulmonary disease and the prevalence of chronic bronchitis estimated to be greater than 3% ([@b44-copd-3-515]). Patients with chronic bronchitis may experience exacerbations (AECBs) of their lung disease with typical complaints of increased dyspnea, productive cough and purulent sputum ([@b4-copd-3-515]). Treatment of all types of exacerbations with antimicrobial agents remains debated but a recent meta-analysis by [@b41-copd-3-515] confirmed the need for antibacterial treatment in the most severe cases of AECB (Type 1). About 50% of patients with chronic bronchitis will have at least 2 exacerbations per year ([@b16-copd-3-515]; [@b31-copd-3-515]), with 20% of these episodes resulting in hospitalizations ([@b31-copd-3-515]). About half of all patients discharged from the hospital for treatment of the exacerbation are readmitted more than once within the following 6 months ([@b43-copd-3-515]). It also appears that frequent AECBs can be associated with a more fulminate decline in FEV~1~ compared to patients without exacerbations ([@b29-copd-3-515]; [@b19-copd-3-515]). Thus, effective treatment of the AECB and consideration for prevention of AECB are major goals in the care of patients with chronic obstructive lung disease.

Since its introduction into the US antibiotic market in 1991, azithromycin has had multiple indications and formulations ([@b20-copd-3-515]). As a 5-day course (5-day formulation; Zpack ^®^) the drug was indicated for the treatment of adults with mild to moderate community acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) and acute bacterial sinusitis (ABS). Additionally, a 3-day formula (TriPak ^®^) and a single dose (Zmax ^®^) have been made available in the US in recent years. The 3-day dosing is indicated for both AECB and ABS whereas the single dose does not currently carry a US FDA indication for the treatment of AECB. These shorter courses of the drug were used in Europe and elsewhere in the world since the early 1990s. Today, these products are available as generics and it is unlikely that future re-formulations of azithromycin will be added to the antibiotic market. This review will evaluate the use of azithromycin in its various formulations for the treatment and prevention of acute exacerbations of COPD.

Zpack^®^ -- 5-day formulation
=============================

The 5-day formulation of azithromycin was the original formulation introduced in the US. At the time of its introduction most acute exacerbations of chronic bronchitis were treated with antimicrobial agents such as tetracyclines, beta lactams, and sulfa drugs. Early trials found that the 5-day formulation of this macrolide was well tolerated and efficacious ([@b14-copd-3-515]; [@b47-copd-3-515]). Further, [@b17-copd-3-515] showed in a retrospective study that newer agents, including azithromycin, significantly impacted AECB in terms of decreased hospitalization rates, longer time between AECB episodes and lower total cost for treatment of the exacerbation. More recent studies have focused on respiratory fluorquinolones as the major comparator to Zpack^®^. Recent studies by [@b16-copd-3-515] and [@b1-copd-3-515] have shown that macrolide antibiotics maintain very good clinical and bacteriological cure rates compared to quinolones. In the Amsden study, levofloxacin was used as a comparator and early cure rates were similar in both arms. Early cure rates were similar between both antibiotics; 89% of azithromycin-treated patients and 92% of levofloxacin-treated patients (p = 0.22). The test of cure in this study (day 24) again showed no significant difference between the favorable response rates for the two treatment groups (82% vs 86%, respectively; p = 0.53). Bacteriological eradication rates did not differ for the two agents when *Haemophilus influenza*, *Streptococcus pneumonia*, and *Mycobacterium catarrhalis* were cultured and evaluated. Interestingly, over half of all enrolled patients in both arms of the study were active smokers but all enrolled patients had to have FEV~1~ \>35% (during exacerbation free testing periods). [@b16-copd-3-515] evaluated 5-day azithromycin versus a similar duration of the fluroquinolone, moxifloxacin. The study population in this study included adults with chronic bronchitis. No mention of FEV~1~ was given in this study and like the Amsden study, approximately 50% of patients in both antibiotic arms were active smokers. Early clinical cure rates were not significantly different; azithromycin 92% and moxifloxacin 91%. The clinical success of the drugs was maintained to the test of cure (days 14--21 post therapy). Microbiological success was very good for both agents although there was a difference between the two drugs for *Haemophilus parainfluenzae* (azithromycin 62%, moxifloxacin 88%). One study has compared azithromycin efficacy to another macrolide, dirithromycin. In this five center study, investigators found that clinical success was not statistically different between the two drugs early (Day 7) or late (Day 30). A summary of the major studies comparing the 5-day formulation of azithromycin to various comparators is shown in [Table 1](#t1-copd-3-515){ref-type="table"}.

TriPak^®^ -- 3-day formulation
==============================

In more recent years, azithromycin has been available as a 3-day formulation in the US. The 3-day formulation has a number of advantages over the 5-day formulation of the drug. First compliance is virtually assured with such a short course of antibiotic therapy. In addition, pharmacokinetic studies have shown that the serum and granulocyte drug concentrations are significant different between the two dosing methods ([@b2-copd-3-515]). [Table 2](#t2-copd-3-515){ref-type="table"} shows 11 various studies comparing the 3-day formulation with various comparators including amoxicillin, amoxicillin-clavulanate, and other macrolides. The efficacy of the 3-day formulation has ranged between 67.6 and 100% for patients cured or improved from AECB at early study time points (\<12 days). Late efficacy (or test of cure) is maintained at levels between 77% and 96%. In all of these studies the 3-day formulation is generally well tolerated with only a minimal increase in gastrointestinal side effects compared with the 5-day formulation.

Although not shown on [Table 2](#t2-copd-3-515){ref-type="table"}, one study has evaluated the clinical efficacy of the 3-day formulation in patients with very severe COPD ([@b9-copd-3-515]). This study by Cazzola et al revealed that 17/21(81%) episodes of acute exacerbations in 65 adult COPD patients were either cured or improved at an early time point (3--5 days post therapy). Patients enrolled in this study had severe to very severe lung disease based on American Thoracic Society criteria and had all received the 23-valent pneumococcal capsular polysaccharide vaccine. Bacteria isolated from the sputum of patients with acute exacerbations showed a variety of pathogens including gram negative bacteria and S. aureus. No *S. pneumoniae* was isolated from the sputum of patients enrolled in this study who had acute exacerbations of their COPD. The main impact of this type of study is that it is more typical of a "real world" scenario; one where most patients with advanced COPD/AECB have received vaccination against pneumococcus. Other groups have attempted to simulate more real world scenarios and gauge AECB outcomes not just on pure clinical or bacteriological criteria but to also use health related quality of life ([@b26-copd-3-515]; [@b38-copd-3-515]; [@b45-copd-3-515]). One of these observational studies, was a prospective, multicenter, observational study evaluating outpatient adults with AECB who received either 3 days of AZM 500 mg/d or 5-- to 14-day courses of standard antibiotics (usual care) as directed by a clinician ([@b38-copd-3-515]). Patients with AECB treated with a 3-day course of azithromycin experienced significant improvements in health related quality of life as measured by a clinical important difference on the St. George's respiratory questionnaire and the SF-36 compared with baseline.

An additional area of interest with the 3-day formulation of azithromycin is the paradox between in vitro antibiotic resistance and in vivo success. Most antibiotic resistance surveillance programs have demonstrated substantial resistance rates for S. pneumoniae and H. influenzae to the macrolide class of antibiotics ([@b18-copd-3-515]; [@b35-copd-3-515]; [@b28-copd-3-515]; [@b39-copd-3-515]; [@b36-copd-3-515]). Despite these bacteriological trends, clinical response to macrolide therapy remains adequate (as indicated by the late clinical cure rates shown in [Table 2](#t2-copd-3-515){ref-type="table"} -- range 77%--96%). Two suggested mechanisms for the paradox between the "petri" dish and the patient exist in the literature. One is the high rate of efflux mediated (*mef* type) resistance among North American isolates of pneumococcus ([@b32-copd-3-515]) in contrast to Europe where most macrolide resistance is methylation mediated (*erm* type). This type of bacterial resistance can be overcome by increasing drug concentration in serum or white blood cells. The second factor in this disparity is that pharmacodynamic differences among the macrolide class at the site of infection plays a critical role in predicting clinical success. Classic macrolides such as erythromycin are time dependent, ie, the amount of time the drug concentration is above the MIC for the organism determines optimal activity. In contrast, for the azalide, azithromycin, optimal activity is dependent on maximizing the area under the concentration-time above the MIC curve (AUIC) ([@b12-copd-3-515]). The dosing regimens of these agents are designed to maximize these pharmacodynamic parameters. [@b23-copd-3-515] have showed that tissue concentrations were above the MIC~90~ for all relevant community-acquired respiratory pathogens, including pneumococci, for at least 8 days after a single 500 mg oral dose of azithromycin ([@b23-copd-3-515]). Thus, the combined effects of overcoming efflux mediated resistance with the unique pharmacodynamic properties of azithromycin make it difficult to rely on standard in vitro assessments of bacteriologic susceptibility. The most current bacterial resistance/surveillance studies have started to assess the prevalence of the various mechanisms of macrolide resistance (ie, efflux versus methylation) ([@b22-copd-3-515]). However, few studies on macrolide resistance evaluate each individual macrolide thus ignoring the potential pharmacodynamic differences of each drug in this class.

Zmax^®^ -- 1-day formulation
============================

A single dose preparation of azithromycin is now also available for utilization in the treatment of respiratory infections. In 2005, the US FDA approved this formulation of the drug for both acute bacterial sinusitis and community acquired pneumonia in adults. The drug is given as a single 2-g dose and the drug is released into the gastrointestinal tract using microsphere technology to minimize side effects (Zmax package insert). Serum and white blood cell concentrations of the 2-g/1-day formulation are substantially higher than the 3-day formulation of azithromycin ([@b34-copd-3-515]). Theoretically, this early peak effect (first 24 hours) may be beneficial to the patient as bacterial burden is likely highest in the first days of treatment of an acute exacerbation. A single study has now been published which evaluates the efficacy of a 1-day formulation for the treatment of AECB ([@b50-copd-3-515]). The comparator in this study is oral levofloxacin which is given for 7 days. In this double-blind, double dummy study comparable clinical cure agents for the two antibiotics were seen late (Days 14--21; 93.6% for azithromycin and 92.7% for levofloxacin). Even in cases of very severe airflow obstruction (FEV~1~ \<30%), azithromycin success rates were high (\>88%).

Azithromycin and prophylaxis for AECB
=====================================

Data are limited about prophylaxis with azithromycin for exacerbations of chronic bronchitis. However, the drug has been used as a prophylactic agent in the cystic fibrosis population to reduce the risk of respiratory exacerbations with moderate success ([@b48-copd-3-515]; [@b40-copd-3-515]; [@b21-copd-3-515]). There have also been at least two trials in patients with obstructive lung disease due to bronchiectasis ([@b15-copd-3-515]). In one study conducted at the Royal Brompton, London, UK, infectious exacerbations decreased from a mean of 0.71 per month to 0.13 per month (p \< 0.001) in 33 patients on 4 months of drug prophylaxis (12 days continuous therapy followed by 250 mg on Mondays, Wednesdays, and Fridays). An additional study in bronchiectasis utilized twice weekly azithromycin (500 mg dose) for a period of 6 months ([@b13-copd-3-515]). Exacerbation incidence and sputum volume measurements were compared from baseline to the end of the study. Among the eleven patients analyzed in this study azithromycin significantly decreased the incidence of exacerbations compared with usual medications (5 vs 16; p = 0.019). Mean sputum volume over a 24-hour 1 period also decreased by approximately 15% (p = 0.005). However, one small European study does suggest a benefit to treating patients with COPD with 500 mg/day for 3 days every 3 weeks ([@b24-copd-3-515]). This study evaluated 54 patients with moderate COPD who were treated during a single winter season. Both hospital admissions and the number of acute infectious exacerbations of COPD were statistically decreased in the azithromycin arm of the study compared to a non-treated control group.

Theoretically, it is possible that the efficacy of azithromycin in these different patient populations (cystic fibrosis and bronchiectasis) may be more related to its immunomodulatory effect rather than its antimicrobial effect. Azithromycin and the other macrolides can decrease neutrophil chemotaxis and infiltration into the respiratory epithelium, downregulate adhension molecule expression and enhance neutrophil apoptosis ([@b30-copd-3-515]; [@b3-copd-3-515]). All of these factors may play significant roles in exacerbations of COPD. To this end, the National Heart, Lung, and Blood Institute and the COPD Clinical Research Network is currently enrolling patients in a multi-center investigation to determine if azithromycin decreases the rate of exacerbations over a 1-year time period ([@b11-copd-3-515]). In this prospective, randomized, double-blind, placebo-controlled study over 1,000 patients with at least moderately severe COPD will be enrolled. Secondary endpoints will include measures of quality of life, the incidence of macrolide-resistant bacterial colonization and cost-effectiveness. Optimistically, this type of trial design will help to definitively determine if prophylactic macrolide therapy can prevent or delay the time between COPD exacerbations.

Conclusion
==========

Azithromycin is a available in three major formulations (1-day, 3-day, and 5-day). All three have had significant success in AECB trials against a wide variety of comparators. Given rising concern about bacterial resistance; the higher strength preparations of azithromycin prescribed over a shorter duration of time offer considerable pharmacodynamic advantages. Future studies will assist in determining the efficacy of this drug in the prevention of exacerbations of chronic bronchitis.
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###### 

Clinical response rates (percent cured and improved) for azithromycin (5-day formulation) versus various comparator(s) at early and late time points

  Study            Year   Comparator                Azithromycin 5-day formulation   Various comparators   Definition of chronic bronchitis          
  ---------------- ------ ------------------------- -------------------------------- --------------------- ---------------------------------- ------ -----
  Dark             1993   Cefaclor                  100.0                            NS                    92.0                               NS     NS
  Whitlock         1995   Amoxicillin-clavulanate   100                              90.0                  93.0                               85.0   ATS
  DeAbate et al    2000   Moxifloxacin              92.0                             88.0                  91.0                               88.0   ATS
  Amsden et al     2003   Levofloxacin              88.9                             81.9                  92.4                               85.6   ATS
  Castaldo et al   2003   Dirithromycin             75.7                             86.5                  84.8                               95.5   ATS

**Abbreviations:** ATS, American Thoracic Society; NS, not stated.

###### 

Clinical response rates (percent cured and improved) for azithromycin (3-day formulation) versus various comparator(s) at early and late time points

  Study               Year   Comparator                Azithromycin 3-day formulation   Various comparators   Definition of chronic bronchitis          
  ------------------- ------ ------------------------- -------------------------------- --------------------- ---------------------------------- ------ ------------------
  Mertens et al       1992   amoxicillin               100.0                            96.0                  92.0                               80.0   ATS
  Bradbury            1993   clarithromycin            95.0                             NS                    97.0                               NS     NS
  Beghi et al         1995   amoxicillin-clavulanate   67.6                             NS                    97.3                               NS     NS
  Biebuyck            1996   amoxicillin-clavulanate   92.1                             95.7                  86.4                               79.6   ATS
  Gris                1996   amoxicillin-clavulanate   86.0                             NS                    92.0                               NS     ATS
  Zachariah           1996   amoxicillin-clavulanate   94.0                             NS                    93.0                               NS     ATS
  Laurent             1996   roxithromycin             NS                               91.2                  88.8                               NS     NS
  Hoepelman et al     1997   amoxicillin-clavulanate   95.0                             77.0                  90.0                               66.0   ATS
  Cazzola et al       1999   dirithromycin             92.5                             89.2                  90.0                               94.4   ATS
  Schouenborg et al   2000   pivampicillin             93.0                             78.0                  86.0                               81.0   ATS
  Swanson et al       2005   clarithromycin            93.0                             85.0                  94.0                               82.0   ATS
  Zervos et al        2007   moxifloxacin              93.0                             89.0                  84.0                               73.0   [@b4-copd-3-515]

**Abbreviations:** ATS, American Thoracic Society; NS, not stated.
